Skip to main content Accessibility help
  • Print publication year: 2000
  • Online publication date: June 2016

Chapter 6 - Endocrine


1. Lacsan A, de Sa DJ. Endocrine system. In Gilbert-Barness E, editor, Potter’s Pathology of the Fetus, Infant and Child, second edn. New York: Mosby Elsevier; 2007;1595–605.
2. McPhie JL, Beck JS. The histological features and human growth hormone content of the pharyngeal pituitary gland in normal and endocrinologically-disturbed patients. Clin. Endocrinol 1973;2:157–73.
3. Weber FT, Donnelly WH, Bejar RL. Hypopituitarism following extirpation of a pharyngeal pituitary. Am. J. Dis. Child. 1977;131:525–8.
4. Bizzarri C, Marini R, Ubertini G, Cappa M. Partially reversible hypopituitarism in an adolescent with a Rathke cleft cyst. Clin. Pediatr. Endocrinol. 2012;21:75–80.
5. Partington MD, Davis DH, Laws ER Jr, Scheithauer BW. Pituitary adenomas in childhood and adolescence. Results of transsphenoidal surgery. J. Neurosurg. 1994;80:209–16.
6. Dyer EH, Civit T, Visot A, Delalande O, Derome P. Transsphenoidal surgery for pituitary adenomas in children. Neurosurgery 1994;34;207–12.
7. Pandey P, Ojha BK, Mahapatra AK. Pediatric pituitary adenoma: A series of 42 patients. J. Clin. Neurosci. 2005;12:124–7.
8. Harrington MH, Casella SJ. Pituitary tumors in childhood. Curr. Opin. Endocrinol. Diabetes Obes. 2012;19:63–7.
9. Jackman S, Diamond F. Pituitary adenomas in childhood and adolescence. Pediatr. Endocrinol. Rev. 2013;10:450–9.
10. Chiloiro S, Bianchi A, Doglietto F, et al. Radically resected pituitary adenomas: prognostic role of Ki 67 labeling index in a monocentric retrospective series and literature review. Pituitary 2013;17:267.
11. Pawlikowski M, Gruszka A, et al. Proliferating cell nuclear antigen (PCNA) expression in pituitary adenomas: relationship to the endocrine phenotype of adenoma. Folia Histochem. Cytobiol. 2006;44:37–41.
12. Hsu DW, Hakim F, Biller BM, et al. Significance of proliferating cell nuclear antigen index in predicting pituitary adenoma recurrence. J. Neurosurg. 1993;78:753–61.
13. Gaston-Massuet C, Andoniadu CL, Signore M, et al. Increased Wingless (Wnt) signaling in pituitary progenitor cells gives rise to pituitary tumors in mice and humans. Proc. Natl. Acad. Sci. USA 2011;108:11482–7.
14. Gaztambide S, Vazquez F, Castaño L. Diagnosis and treatment of multiple endocrine neoplasia type 1 (MEN1). Minerva Endocrinol. 2013;38:17–28.
15. Delemer B. MEN 1 and pituitary adenomas. Ann. Endocrinol. (Paris) 2012;73:59–61.
16 Raff SB, Carney JA, Krugman D, Doppman JL, Stratakis CA. Prolactin secretion abnormalities in patients with the “syndrome of spotty skin pigmentation, myxomas, endocrine overactivity and schwannomas” (Carney complex). J. Clin. Endocrinol. Metabol. 2000;13:373–9.
17. Cohen MM Jr, Howell RE. Etiology of fibrous dysplasia and McCune- Albright syndrome. Int. J. Oral Maxillofac. Surg. 1999;28:366–71.
18. Stratakis CA, Tichomirowa M, Boikos S, et al. The role of germline AIP, MEN1, PRKAR1 A, CDKN 1B, CDKN 2C mutations causing pituitary adenomas in a large cohort of children, adolescents, and patients with genetic syndromes. Clin. Genet. 2010;78:457–63.
19. Leontiou CA. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. J. Clin. Endocrinol. Metabol. 2008;93:2390–401.
20. Noh SJ, Ahn JY, Lee KS, Kim SH. Pituitary adenoma and concomitant Rathke’s cleft cyst. Acta Neurochir. (Wien) 2007;149:1223–8.
21. Karavitaki N, Scheithauer BW, Watt J, et al. Collision lesions of the sella: coexistence of craniopharyngioma with gonadotroph adenoma and of Rathke’s cleft cyst with corticotroph adenoma. Pituitary 2008;11:317–23.
22. Furtado SV, Thakar S, Ghosal N, Hegde AS. Atypical presentation of pediatric mixed germ cell tumors in the sellar and suprasellar region. Neurol. India 2012;60:90–3.
23. Cemeroglu AP, Blaivas M, Muraszko KM, Robertson, PL, Vazquez DM. Lymphocytic hypophysitis presenting with diabetes insipidus in a 14 year-old girl: case report and review of the literature. Eur. J. Pediatr. 1997;156:684–8.
24. Rousseau-Nepton I, Kaduri S, Garfield N, Krishnamoorthy P. Hypothalamic hamartoma associated with central precocious puberty and growth hormone deficiency. J. Pediatr. Endocrinol. Metab. 2013;10:1–5.
25. Stoll C, De Saint Martin A, Donato L, et al. Pallister-Hall syndrome with stenosis of the cricoid cartilage and microphallus without hypopituitarism. Genet. Couns. 2001;12:231–5.
26. Peña S, Robertson H, Walvekar RR. Thyroid Hemiagenesis: Report of a Case and Review of Literature. Indian. J. Otolaryngol. Head Neck Surg. 2011;63:198–200.
27. Robinson HB Jr. Di George’s or the III-IV pharyngeal pouch syndrome: pathology and a theory of pathogenesis. Perspect. Pediatr. Pathol. 1975;3:173–206.
28. Pueblitz S, Weinberg G, Albores Saavedra J. Thyroid C cells in the Di George syndrome. Pediatr. Pathol. 1993;13:463–73.
29. Altay C, Erdogan N, Karasu S, et al. CT and MRI findings of developmental abnormalities and ectopia varieties of the thyroid gland. Diagn. Interv. Radiol. 2012;18:335–43.
30. Dzodic R, Markovic I, Stanojevic B, et al. Surgical management of primary thyroid carcinoma arising in thyroglossal duct cyst: An experience of a single institution in Serbia. Endocr. J. 2012;59:517–22.
31. Triglia JM, Nicollas R, Ducroz V. et al. First branchial cleft anomalies: A study of 39 cases and a review of the literature. Arch. Otolaryngol. Head Neck Surg. 1998;124:291–5.
32. Thomas B, Shroff M, Forte V, Blaser S, James A. Revisiting imaging features and the embryologic basis of third and fourth branchial anomalies. Am. J. Neuroradiol. 2010;31:755–60.
33. Michels AW, Eisenbarth GS. Immunologic endocrine disorders. J. Allergy Clin. Immunol. 2010;125(Suppl 2):S226–37.
34. Ahn D, Heo SJ, Park JH, et al. Clinical relationship between Hashimoto thyroiditis and papillary thyroid cancer. Acta Oncol. 2011;50:1228–34.
35. Mukasa K, Noh JY, Kunii Y, et al. Prevalence of malignant tumors and adenomatous lesions detected by ultrasonographic screening in patients with autoimmune thyroid diseases. Thyroid 2011;21:37–41.
36. Mssrouri R, Benamr S, Essadel A et al. Thyroid cancer in patients with Grave’s Disease. J. Chir. (Paris) 2008; 145:244–6.
37. Rago T, Fiore E, Scutari M, Santini F, et al. Male sex, single nodularity, and young age are associated with the risk of finding a papillary thyroid cancer on fine-needle aspiration cytology in a large series of patients with nodular thyroid disease. Eur. J. Endocrinol. 2010;162:763–70.
38. Bradly DP, Reddy V, Prinz RA, Gattuso P. Incidental papillary carcinoma in patients treated surgically for benign thyroid diseases. Surgery 2009;146:1099–104.
39. Conran RM, Askin FB, Dehner LP. The pineal, pituitary, parathyroid, thyroid and adrenal glands. In: Stocker JT, Dehner LP, editors, Pediatric Pathology, second edn. Philadelphia: Lippincott Williams & Wilkins; 2001;1028–40.
40. Park SM, Chatterjee VK. Genetics of congenital hypothyroidism. J. Med. Genet. 2005;42:379–89.
41. Kennedy JS. The pathology of dyshormonogenetic goiter. J. Pathol. 1969;99:251–64.
42. Piciu D, Piciu A, Irimie A. Thyroid cancer in children: A 20-year study at a Romanian oncology institute. Endocr. J. 2012;59:489–96.
43. Jaruratanasirikul S, Leethanaporn K, Khuntigij P, Sriplung H. The clinical course of Hashimoto’s thyroiditis in children and adolescents: 6 years longitudinal follow-up. J. Pediatr. Endocrinol. Metab. 2001;14:177–84.
44. Roy R, Kouniavsky G, Schneider E, et al. Predictive factors of malignancy in pediatric thyroid nodules. Surgery 2011;150:1228–33.
45. Redlich A, Boxberger N, Kurt Werner S, et al. Sensitivity of fine-needle biopsy in detecting pediatric differentiated thyroid carcinoma. Pediatr. Blood Cancer 2012;59:233–7.
46. Collini P, Mattavelli F, Pellegrinelli A, et al. Papillary carcinoma of the thyroid gland of childhood and adolescence: Morphologic subtypes, biologic behavior and prognosis: A clinicopathologic study of 42 sporadic cases treated at a single institution during a 30-year period. Am. J. Surg. Pathol. 2006;30:1420–61.
47. Desai D, McPherson LA, Higgins JP, Weigel RJ. Genetic analysis of a papillary thyroid carcinoma in a patient with MEN1. Ann. Surg. Oncol. 2001;8:342–6.
48. Nosé V. Familial non-medullary thyroid carcinoma: An update. Endocr. Pathol. 2008;19:226–40.
49. Enomoto K, Enomoto Y, Uchino S, Yamashita H, Noguchi S. Follicular thyroid cancer in children and adolescents: clinicopathologic features, long-term survival, and risk factors for recurrence. Endocr. J. 2013;60:629–35.
50. Lloyd RV, Philipp U. Heitz, Charis E. WHO Tumors of Endocrine Organs. World Health Organization Classification of Tumors DeLellis RA, editor. Lyon: IARC Press, 2004.
51. Hall JE, Abdollahian DJ, Sinard RJ. Thyroid disease associated with Cowden syndrome: A meta-analysis. Head Neck 2013;35:1189–94.
52. Wells SA Jr, Pacini F, Robinson BG, Santoro M. Multiple endocrine neoplasia type 2 and familial medullary thyroid carcinoma: An update. J. Clin. Endocrinol. Metab. 2013;98:3149–64.
53. Mete O, Asa SL. Precursor lesions of endocrine system neoplasms. Pathology 2013;45:316–30.
54. Williams ED, Brown CL, Doniach I. Pathological and clinical findings in a series of 67 cases of medullary carcinoma of the thyroid. J. Clin. Pathol. 1966;19:103–13.
55. Pacini F, Basolo F, Elisei R, et al. Medullary thyroid cancer. An immunohistochemical and humoral study using six separate antigens. Am. J. Clin. Pathol. 1991;95:300–8.
56. Tavares MR, Toledo SP, et al. Surgical approach to medullary thyroid carcinoma associated with multiple endocrine neoplasia type 2. Clinics (Sao Paulo) 2012; 67 Suppl 1:149–54.
57. Roth S, Abu–Jawdeh GM. Parathyroid glands. In S. S. Sternberg, editor, Histology for Pathologists, second edn. Philadelphia: Lippincott-Raven 1997:1093–105.
58. Wang C-A. The anatomic basis of parathyroid surgery. Ann. Surg. 1976;183:271–75.
59. Lack EE, Delay S, Linnoila RI. Ectopic parathyroid tissue within the vagus nerve. Arch. Pathol. Lab. Med. 1988;112:304–6.
60. Neumann DR, Esselstyn CB Jr, Madera A, Wong CO, Lieber M. Parathyroid detection in secondary hyperparathyroidism with 123I/99m Tc-sestamibi subtraction single photon emission computed tomography. J. Clin. Endocrinol. Metabol. 1998;83:3867–71.
61. Kurman RJ, Prabha AC. Thyroid and parathyroid glands in the vaginal wall: report of a case. Am. J. Clin. Pathol. 1973;59:503–7.
62. Reddick, RL, Costa JC, Marx SJ. Parathyroid hyperplasia and parathyromatosis. Lancet 1977;1:549 (letter).
63. Su D, Ellis S, Napier A, Manley NR. Hoxa3 and pax1 regulate epithelial cell death and proliferation during thymus and parathyroid organogenesis. Dev. Biol. 2001;236:316–29.
64. Zou D, Silvius D, Davenport J, et al. Patterning of the third pharyngeal pouch into the thymus/parathyroid by Six and Eya 1. Dev. Biol. 2006;293:499–512.
65. Rodriguez Soriano J. Branchio-oto-renal syndrome. J. Nephrol. 2003;16:603–5.
66. Shannon WA, Roth SI. Ultrastructural study of acid phosphatase activity in normal, adenomatous and hyperplastic (chief cell type) human parathyroid glands. Am. J. Pathol. 1974;77:493–506.
67. DeLellis RA. Atlas of Tumor Pathology: Tumors of the Parathyroid Gland 3rd Series. Washington DC: Armed Forces Institute of Pathology,1991.
68. Bronsky D, Kiamko RT, Moncada R, Rosenthal IM. Intrauterine hyperparathyroidism secondary to maternal hypoparathyroidism. Pediatrics 1968;42:606–8.
69 Okonofua F, Menon RK, Houlder S, et al. Parathyroid hormone and neonatal calcium homeostasis: evidence for secondary hyperparathyroidism in the Asian neonate. Metabolism 1986;35:803–6.
70. Fukuoka H, Mukai S, Kobayashi Y, Jimbo T. Dynamic changes in serum osteocalcin levels in the perinatal period. Nihon Naibuni Gakkai Zasshi 1989;65:1116–22.
71. Sulaiman RA, Sharratt CL, Lee PW, et al. Ethnic differences in umbilical cord blood vitamin D and parathyroid hormone – South Asians compared to Whites born in the UK. J. Matern. Fetal Neonatal Med. 2010;23:1315–17.
72. Lothe A, Sinn J, Stone M. Metabolic bone disease of prematurity and secondary hyperparathyroidism. J. Paediatr. Child. Health 2011;47:550–3.
73. Keynes WM, Truscott BM. Large solitary cysts of the parathyroid gland. Br. J. Surg. 1956;44:23–4.
74. Lydiatt DD, Byers RM, Khouri KG, Whitworth PW, Sellin RV. Functional parathyroid cyst and hypocalciuric hypercalcemia. Ear Nose Throat J. 1993:72:142–4.
75. Dell’amore A, Asadi N, Bartalena T, Bini A, Stella F. Thoracoscopic resection of a giant mediastinal parathyroid cyst. Gen. Thorac. Cardiovasc. Surg. 2013 (Epub ahead of print).
76. Gayatri P, Sanjay D, Ajay N, Amrut A. Mixed multilocular ectopic thymic cyst with parathyroid element presenting as neck mass. Ann. Acad. Med. Singapore 2012;41:271–2.
77. Daum F, Rosen JF, Boley SJ. Parathyroid adenoma, parathyroid crisis, and acute pancreatitis in an adolescent. J. Pediat. 1973;83:273–5.
78. Young TO, Saltzstein EC, Boman DA. Parathyroid carcinoma in a child: unusual presentation with seizures. J. Pediatr. Surg. 1984;19:194–200.
79. Meier DE, Snyder WH 3rd, Dickson BA, Margraf LR, Guzzetta PC Jr. Parathyroid carcinoma in a child. J. Pediatr. Surg. 1999;34:606–8.
80. Fiedler AG, Rossi C, Gingalewski CA. Parathyroid carcinoma in a child: An unusual case of an ectopically located malignant parathyroid gland with tumor invading the thymus. J. Pediatr. Surg. 2009;44:1649–52.
81. Herrera-Hernandez AA, Aranda-Valderrama P, Diaz-Perez JA, Herrera LP. Intrathyroidal parathyroid carcinoma in a pediatric patient. Pediatr. Surg. Int. 2011;27:1361–5.
82. Li CC, Yang C, Wang S, et al. A 10 year retrospective study of primary hyperparathyroidism in children. Exp. Clin. Endocrinol. Diabetes 2012;120:229–33.
83. Grimelius L, Akerstrom G, Johansson H, Juhlin C, Rastad J. The parathyroid glands. In Kovacs K, Asa S, editors, Functional Endocrine Pathology. Boston: Blackwell Scientific, 1990:375–95.
84. Ippolito G, Palazzo FF, Sebag F, De Micco C, Henry JF. Intraoperative diagnosis and treatment of parathyroid cancer and atypical parathyroid adenoma. Br. J. Surg. 2007;94(5):566–70.
85. Benaderet AD, Burton AM, Clifton-Bligh R, Ashraf AP. Primary hyperparathyroidism with low intact PTH levels in a 14- year-old girl. J. Clin. Endocrinol. Metabol. 2011;96:2325–9.
86. Wesseling K, Bakkaloglu S, Salusky I. Chronic kidney disease mineral and bone disorder in children. Pediatr. Nephrol. 2008;23:195–207.
87. Wesseling-Perry K. Bone disease in pediatric chronic kidney disease. Pediatr. Nephrol. 2013;28:569–76.
88. Wilhelm-Bals A, Parvex P, Magdelaine C, Girardin E. Successful use of biphosphonate and calcimimetic in neonatal severe primary hyperparathyroidism. Pediatrics 2012;129:812–16.
89. Hannan FM, Thakker RV Calcium-sensing receptor (CaSR) mutations and disorders of calcium, electrolyte and water metabolism. Best. Pract. Res. Clin. Endocrinol. Metab. 2013;27:359–71.
90. Giusti F, Marini F, Brandi ML. Multiple endocrine neoplasia type 1. In Pagon RA, Adam MP, Bird TD, Dolan CR, Fong CT, Stephens K, editors, GeneReviews™ (Internet). Seattle, WA: University of Washington, Seattle, 1993–2013.
91. Lipps CJ, Dreijerink KM, Hoppener JW. Variable clinical expression in patients with a germline MEN1 disease gene mutation: clues to a genotype –phenotype correlation. Clinics (Sao Paulo) 2012;67:(S1)49–56.
92. Marini F, Falchetti A, Del Monte F, et al. Multiple endocrine neoplasia type 2. Orphanet. J. Rare Dis. 2006;2:1–38.
93. Chandrasekharappa SC, Guru SC, Manickam P, et al. Positional cloning of the gene for multiple endocrine neoplasia-type 1. Science 1997;276:404–407.
94. Dreijerink KM, Lips CJ, Timmers HT. Multiple endocrine neoplasia type 1: A chromatin writer’s block. J. Intern. Med. 2009;266(1):53–9.
95. Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J. Clin. Endocrinol. Metab. 2012;97:2990–3011.
96. Wagner SM, Zhu S, Nicolescu AC, Mulligan LM. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2. Clinics (Sao Paulo) 2012;67 Suppl 1:77–84.
97. Zenaty D, Aigrain Y, Peuchmar M, et al. Medullary thyroid carcinoma identified within the first year of life in children with hereditary multiple endocrine neoplasia type 2A (codon 634) and 2B. Eur. J. Endocrinol. 2009;160:807–13.
98. Jabbour SA, Davidovici BB, Wolf R. Rare syndromes. Clin. Dermatol. 2006;24:299–316.
99. Lora MS, Waguespack SG, Moley JF, Walvoord EC. Adrenal ganglioneuromas in children with multiple endocrine neoplasia type 2: A report of two cases. J. Clin. Endocrinol. Metab. 2005;90:4383–7.
100. Lee NC, Norton JA. Multiple endocrine neoplasia type 2B–genetic basis and clinical expression. Surg. Oncol. 2000;9:111–8.
101. Raue F, Frank-Raue K. Genotype-phenotype correlation in multiple endocrine neoplasia type 2. Clinics (Sao Paulo) 2012;67 Suppl 1:69–75.
102. Willis RA. The Borderland of Embryology and Pathology. London: Butterworths, 1958:326–9.
103. Vestfrid MA. Ectopic adrenal cortex in neonatal liver. Histopathology 1980;4;669–72.
104. Wright JR Jr, Gillis DA. Mediastinal foregut cyst containing an intramural adrenal cortical rest: A case report and review of supradiaphragmatic adrenal rests. Pediatr. Pathol. 1993;13:401–7.
105. Knape P, Reisch N, Dorr HG, et al. Testicular rest tumors (TART) in adult men with classic congenital adrenal hyperplasia (CAH). Urologe A 2008:1596–7,1599–602.
106. Claahsen-van der Grinten HL, Otten BJ, Stikkelbroek MM, Sweep FC, Hermus AR. Testicular adrenal rest tumors in congenital adrenal hyperplasia. Best Pract. Res. Clin. Endocrinol. Metab. 2009;23:209–20.
107. Mouritsen A, Jorgensen N, Main KM, Schwartz M, Juul A. Testicular adrenal rest tumors in boys, adolescents and adult men with congenital adrenal hyperplasia may be associated with the CYP21A2 mutation. Int. J. Androl. 2010;33:521–7.
108. Wiedemann HR. Complex familiale avec hernie ombilicale et macroglossie –un sybndrome nouveau. J. Genet. Hum. 1964;13:223–32.
109. Beckwith JB. Macroglossia, omphalocele, adrenal cytomegaly, gigantism and hyperplastic visceromegaly. Birth Defects Orig. Artic. Series 1969;5:188–96.
110. Cooper WN, Luharia A, Evans GA, et al. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur. J. Hum. Genet. 2005;13:1025–32.
111. Aterman K, Kerenyi N, Lee M. Adrenal cytomegaly. Virchows Arch. A 1972;355:105–22.
112. Esterly JR, Oppenheimer EH. Intrauterine rubella infection. Perspect. Pediatr. Pathol. 1973;1:313–38.
113. Nakamura Y, Komatsu Y, Yano H, et al. Non immunologic hydrops fetalis; a clinicopathologic study of 50 autopsy cases. Pediatr. Pathol. 1987;7:19–30.
114. Camuto PM, Wolman SR, Perle MA, Greco MA. Flow cytometry of fetal adrenal glands with adrenocortical cytomegaly. Pediatr. Pathol. 1989;9:551–8.
115. Favara BE, Steele A, Grant JH, Steele P. Adrenal cytomegaly: quantitative assessment by image analysis. Pediatr. Pathol. 1991;11:521–36.
116. Ong BB, Wong KT. Adrenal cytomegaly associated with diaphragmatic hernia: report of a case. Malays. J. Pathol. 1996;18:121–123.
117. Skogseid B, Larsson C, et al. Clinical and genetic features of adrenocortical lesions in multiple endocrine neoplasia type 1. J. Clin. Endocrinol. Metab. 1992;75:76–81.
118. Kirk KM, Brain CE, Carson DJ, Hyde JC, Grant DB. Cushing’s syndrome caused by nodular adrenal hyperplasia in children with McCune-Albright syndrome. J. Pediatr. 1999;134:789–92.
119. Stratakis CA, Jenkins RB, Pras E, et al. Cytogenetic and microsatellite alterations in tumors from patients with the syndrome of myxomas, spotty skin pigmentation, and endocrine overactivity (Carney complex). J. Clin. Endocrinol. Metab. 1996;81:3607–14.
120. Croitoru DP, Sinsky AB, Laberge JM. Cystic neuroblastoma. J. Pediatr. Surg. 1992;27:1320–1.
121. Sethuraman C, Rutter S, Drut R, et al. Bilateral absence of adrenal glands: A case series that expands the spectrum of associations and highlights the difficulties in prenatal diagnosis. Fetal Pediatr. Pathol. 2011;30:137–43.
122. Agrons GA, Lonergan GJ, Dickey GE, Perez-Monte JE. Adrenocortical neoplasm’s in children: radiologic-pathologic correlation. Radiographics 1999;19:989–1008.
123. Michalkiewicz E, Sandrini R, et al. Clinical and outcome characteristics of children with adrenocortical tumors: A report from the International Pediatric Adrenocortical Tumor Registry. J. Clin. Oncol. 2004;22:838–45.
124. Che QL, Su Z, Li YH, et al. Clinical characteristics of adrenocortical tumors in children. J. Pediatr. Endocrinol. Metab. 2011;24:535–41.
125. Micic D, Zoric S, Popovic V, et al. Androgen-producing bilateral large cortical adrenal adenomas associated with polycystic ovaries in a young female. Postgrad. Med. J. 1992;68:219–22.
126. Driver CP, Birch J, Gough DC, Bruce J. Adrenal cortical tumors in childhood. Pediatr. Hematol. Oncol. 1998;15:527–32.
127. Bornstein SR, Stratakis CA, Chrousos GP. Adrenocortical tumors: recent advances in basic concepts and clinical management. Ann. Intern. Med. 1999;130:759–71.
128. Sasano H, Suzuki T, Moriya T. Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr. Pathol. 2006;17:345–54.
129. van’t Sant HP, Bouvy ND, Kazemier G, et al. The prognostic value of two different histopathological scoring systems for adrenocortical carcinomas. Histopathology 2007;51:239–45.
130. Lau SK, Weiss LS. The Weiss system for evaluating the adrenocortical neoplasms: 25years later. Hum. Pathol. 2009;40:757–68.
131. Papotti M, Libe R, Duregon E, et al. The Weiss score and beyond – histopathology for adrenocortical carcinoma. Hum. Cancer 2011;2:333–49.
132. Faria AM, Almeida MQ. Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults. Mol. Cell. Endocrinol. 2012;351:52–7.
133. de Krijger RR, Papathomas TG. Adrenocortical neoplasia; evolving concepts in tumorigenesis with an emphasis on adrenal cortical carcinoma variants. Virchows Arch. 2012;460:9–18.
134. Cagle PT, Hough AJ, Pysher TJ, et al. Comparison of adrenal cortical tumors in children and adults. Cancer 1986;57:2235–7.
135. Lack EE, Mulvihill JJ, Travis WD, Kozakewich HP. Adrenal cortical neoplasms in the pediatric and adolescent age group. Clinicopathologic study of 30 cases with emphasis on epidemiological and prognostic factors. Pathol. Annu. 1992;27:1–53.
136. Li FP, Fraumeni JF Jr. Rhabdomyosarcoma in children: epidemiologic study and identification of a familial cancer syndrome. J. Natl. Cancer Inst. 1969;43:1365–73.
137. Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol. Cell. Endocrinol. 2012;351:66–70.
138. Rodriguez-Galindo C, Figueiredo BC, Zambetti GP, Ribeiro RC. Biology, clinical characteristics and management of adrenocortical tumors in children. Pediatr. Blood Cancer 2005;45:265–73.
139. Fonseca AL, Kugelberg J, Starker LF, Scholl U, Choi M, et al. Comprehensive DNA methylation analysis of benign and malignant adrenocortical tumors. Genes Chromosomes Cancer 2012;51:949–60.
140. Rothenbuler A, Horvath A, Libe R, et al. Identification of novel genetic variants in phosphodiesterase (PDE8B), a camp-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with tumors. Clin. Endocrinol. (Oxf) 2012;77:195–9.
141. Singh P, Soon PS, Feige JJ, et al. Dysregulation of microRNAs in adrenocortical tumors. Mol. Cell. Endocrinol. 2012;351:118–28.
142. Lack EE. The adrenal gland. In Silverberg SS, De Lellis RA, Frable WJ, editors, Principles and Practice of Surgical Pathology and Cytopathology, third edn. New York: Churchill-Livingstone, 1997:2751–99.
143. DeLellis RA, Wolfe H, Gagel RT, et al. Adrenal medullary hyperplasia. A morphometric analysis in patients with familial medullary thyroid carcinoma. Am. J. Pathol. 1976;83:177–96.
144. Erlic Z, Neumann HP. Familial pheochromocytoma. Hormones (Athens) 2009;8:29–38.
145. Kumar M, Kumar V, Talukdar B, Mohta A, Khurana N. Cushing syndrome in an infant due to cortisol secreting adrenal pheochromocytoma: A rare association. J. Pediatr. Endocrinol. Metab. 2010;23:621–5.
146. Amar L, Bertherat J, Baudin E, et al. Genetic testing in pheochromocytoma or functional paraganglioma. J. Clin. Oncol. 2005;23:8812–18.
147. Carney JA, Sizemore GW, Sheps SG. Adrenal medullary disease in multiple endocrine neoplasia 2. Am. J. Clin. Pathol. 1976;66:279–90.
148. Rosai J. Adrenal and other paraganglia. In Rosai and Ackerman’s Surgical Pathology, tenth edn. Oxford: Elsevier Mosby; 2011;1076–8.
149. Neville AM. The adrenal medulla. In Symington T, editor, Functional Pathology of the Adrenal Gland. Baltimore: Williams and Wilkins; 1969;219–34.
150. Scott HW Jr, Halter SA. Oncologic aspects of pheochromocytoma: the importance of follow-up. Surgery 1984;96:1061–6.
151. Shimada H, Ambros IM, Dehner LP, et al. Terminology and morphologic criteria of neuroblastic tumors: Recommendation by the International Neuroblastoma Pathology Committee. Cancer 1999;86:349–93.
152. Joshi VV. Peripheral neuroblastic tumors: pathologic classification based on recommendations of International Neuro blastoma Pathology Committee (modification of Shimada classification). Pediatr. Dev. Pathol. 2000;3:184–99.
153. Orbach D, Sarnacki S, Brisse HJ, et al. Neonatal cancer. Lancet Oncol. 2013;14(13):e609–20.
154. Turkel SB, Itabashi HH. The natural history of neuroblastic cells in the fetal adrenal glands. Am. J. Pathol. 1974;76:225–44.
155. Beckwith JB, Perrin EV. In situ neuroblastomas: A contribution to the natural history of neural crest Tumors. Am. J. Pathol. 1963;43:1089–104.
156. Kincaid OW, Hodgson JR, Dockerty MB. Neuroblastoma: A roentgenologic and pathologic study. Am. J. Rontgenol. Radium Ther. Nucl. Med. 1957;78:420–36.
157. Evans AE, D’Angio GJ, Randolph J. A proposed staging for children with neuroblastoma. Cancer 1971;27:374–8.
158. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J. Clin. Oncol. 1993;11:1466–77.
159. Hachitanda Y, Hata J. Stage IV S neuroblastoma: A clinical, histological and biological analysis of 45 cases. Hum. Pathol. 1996;27:1135–8.
160. Schneiderman J, London WB, Brodeur GM, et al. Clinical significance of MYCN amplification and ploidy in favorable-stage neuroblastoma: A report from the Children’s Oncology Group. J. Clin. Oncol. 2008;26:913–18.
161. Brodeur GM, Green AA, et al. Cytogenetic features of human neuroblastomas and cell lines. Cancer Res. 1981;41:4678–86.
162. Gilbert F, Balaban G, Moorhead P, Bianchi D, Schlesinger H. Abnormalities of chromosome 1p in human neuroblastoma Tumors and cell lines. Cancer Genet. Cytogenet. 1982;7:33–42.
163. Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science 1984;224(4653):1121–4.
164. Seeger RC, Brodeur GM, Sather H, et al. Association of multiple copies of the N-myc oncogene with rapid progression of neuroblastomas. N. Engl. J. Med. 1985;313:1111–16.
165. Nakagawara A, Arima-Nakagawara M, Scavarda NJ, et al. Association between high levels of expression of the TRK gene and favorable outcome in human neuroblastoma. N. Engl. J. Med. 1993;328:847–54.
166. Chan H, Haddad G, Thorner PS, et al. P-glycoprotein expression as a predictor of the outcome of therapy for neuroblastoma. N. Engl. J. Med. 1991;325:1608–14.
167. George RE, London WB, Cohn SL, et al. Hyperdiploid plus non amplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: A Pediatric Oncology Group study. J. Clin. Oncol. 2005;23(27):6466–73.
168. Goto S, Umehara S, Gerbing RB, et al. Histopathology and MYCN status in peripheral neuroblastic tumors: A report from the Children’s Cancer Group. Cancer 2001;92:2699–708.
169. Miller MA, Ohashi K, Zhu X, et al. Survivin mRNA levels are associated with biology of disease and patient survival in neuroblastoma: A report from the Children’s Cancer Group. J. Pediatr. Hematol. Oncol. 2006;28:412–17.
170. Krams M, Heidebrecht HJ, Hero B, et al. Repp86 expression and outcome in patients with neuroblastoma. J. Clin. Oncol. 2003;21:1810–18.
171. Oberthuer A, Hero B, Spitz R, et al. The tumor-associated antigen PRAME is universally expressed in high stage neuroblastoma and associated with poor outcome. Clin. Cancer Res. 2004;10:4307–13.
172. Shimada H, Nakagawa A, Peters J, et al. TrkA expression in peripheral neuroblastic tumors: prognosis, significance and biological relevance. Cancer 2004;101;1873–81.
173. Kai-Oliver H, Bauer T, Schulte J, et al. CAMTA1, a 1p36 tumor suppressor candidate, inhibits growth and activates differentiations programs in neuroblastoma cells. Cancer Res. 2011;15:3142–51.
174. Wei JS, Greer BT, Westermann F, et al. Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma. Cancer Res. 2004;64:6883–91.
175. Cohn SL, Pearson ADJ, London WB, et al. The International Neruoblastoma Risk Group (INRG) Classification System: An INRG task force report. J. Clin. Oncol. 2009; 27:289–97.
176. De Vathaire F, Francois P, Schlumberger M, et al. Epidemiological evidence for a common mechanism for neuroblastoma and differentiated thyroid tumor. Br. J. Cancer 1992;65:425–8.
177. Hadjigeorgi C, Lafoyianni S, Pontikis Y, Van Vliet-Constantinidiou C. Asymptomatic myelolipoma of the adrenal. Pediatr. Radiol. 1992;22:465–6.
178. Cobanoglu U, Yaris N, Cay A. Adrenal myelolipoma in a child. Pediatr. Surg. Int. 2005;21:500–2.
179. Cardinalli IA, de Oliveira-Filho AG, Mastellaro MJ, Ribeiro RC, Aguilar SS. A unique case of synchronous functional adrenocortical adenoma and myelolipoma within the ectopic adrenal cortex in a child with Beckwith-Wiedemann Syndrome. Pathol. Res. Pract. 2012;208:189–94.
180. Arzanian MT, Khaleghnejad-Tabari A, et al. Generalized myelolipoma. Arch. Iran. Med. 2006;9:274–6.
181. Munns CFJ, Batch JA. The endocrine pancreas of the neonate and infant. Perspect. Pediatr. Pathol. 1982:7:137–65.
182. Milner RD, Wirdnam PK, Tsanakas J. Quantitave morphology of B, A, D, and PP cells in infants of diabetic mothers. Diabetes 1981;30:271–4.
183. Fukuzawa R, Umezawa A, et al. Nesidioblastosis and mixed hamartoma of the liver in Beckwith-Wiedemann syndrome: case study including analysis of H19 methylation and insulin-like growth factor 2 genotyping and imprinting. Pediatr. Dev. Pathol. 2001;4:381–90.
184. Neri G, Martini-Neri ME, Katz BE, Opitz JM. The Perlman syndrome: Familial renal dysplasia with Wilms tumor, fetal gigantism and multiple congenital anomalies. Am. J. Genet. A 2013;161:2691–6.
185. Patton RG, Christie DL, Smith DW, Beckwith JB. Cerebro-hepato-renal syndrome of Zellweger. Two patients with islet cell hyperplasia, hypoglycemia, and thymic anomalies, and comments on iron metabolism. Am. J. Dis. Child. 1972;124:840–4.
186. Halvorsen S, Pande H, Loken AC, Gjessing LR. Tyrosinosis. A study of 6 cases. Arch. Dis. Child. 1966;41:238–49.
187. Dickson PI, Briones NY, et al. Costello syndrome with pancreatic cell hyperplasia. Am. J. Genet. A 2004;130A:402–5.
188. Suh YL, Khang SK, Kim KN. Neonatal hemochromatosis- a report of an autopsy case. J. Korean Med. Sci. 1999;6:267–72.
189. Laidlaw, GF. Nesidioblastoma, islet tumor of pancreas. Am. J. Pathol. 1938;14:125–34.
190. Yakovac WC, Baker L, Hummeler K. Beta cell nesidioblastosis in idiopathic hypoglycemia of infancy. J. Pediatr. 1971;79:226–31.
191. Aynsley-Green, Hussain K, et al. Practical management of hyperinsulinism in infancy. Arch. Dis. Child. Fetal Neonatal Ed. 2000;82:F98–107.
192. Dunne MJ, Cosgrove KE, Shepherd RM, Aynsley-Green A, Lindley KJ. Hyperinsulinism in Infancy: From basic science to clinical disease. Physiol. Rev. 2004;84:239–75.
193. Rahier J, Sempoux C, Fournet JC, et al. Partial or near total pancreatectomy for persistent neonatal hyperinsulinaemic hypoglycaemia: the pathologist’s role. Histopathology 1998; 32:15–19.
194. Jack MM, Walker RM, Thomsett MJ, Cotterill AM, Bell JR. Histologic findings in persistent hyperinsulinemic hypoglycemia of infancy: Australian experience. Pediatr. Devel. Pathol. 2000;3:532–47.
195. Sempoux C, Capito C, Bellané-Chantelot et al. Morphological mosaicism of the pancreatic islets: A novel anatomopathological form of persistent hyperinsulinemic hypoglycemia of infancy. J. Endocrinol. Metab. 2011;96:3785–93.
196. Arbizu Lostao J, Fernandez-Marmiesse A, et al. 18F-fluoro-L-DOPA PET-CT imaging combined with genetic analysis for optimal classification and treatment in a child with severe congenital hyperinsulinism. Ann. Pediatr. 2008;68(5):481–5.
197. Von Rohden L, Mohnike K, Mau H, et al. Intraoperative sonography: A technique for localizing focal forms of congenital hyperinsulinism in the pancreas. Ultraschall. Med. 2011,32:74–80.
198. Arnoux JB, Verkarre V et al. Congenital hyperinsulinism: current trends in diagnosis and therapy. Orphanet. J. Rare Dis. 2011;6:63.
199. Giurgea I, Bellane-Chantelot C, Ribeiro M, et al. Molecular mechanisms of neonatal hyperinsulinism. Horm. Res. 2006;66:289–96.